The pharmacologic therapy of rosacea: A paradigm shift in progress

Cutis

Volumn 75, Issue 3 SUPPL., 2005, Pages 27-32

  Bikowski, Joseph B ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}  

^a 3M Pharmaceuticals ^*  (United States)

^b 3M COMPANY   (United States)

^c ALLERGAN INC   (United States)

^d Aventis

^e Berlex Laboratories   (United States)

^f BIOGEN   (United States)

^g Managed Care and Professional Affairs   (United States)

^h Dermik Laboratories   (United States)

ⁱ ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^j Galderma Laboratories   (United States)

^k GLAXOSMITHKLINE   (United Kingdom)

^l Healthpoint Ltd   (United States)

^m Text Mining Services   (Switzerland)

ⁿ Stiefel Laboratories Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTICIN; ADAPALENE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMNESTEEM; ANTIBIOTIC AGENT; AVAR GEL; AVAR GEL GREEN; AZELAIC ACID; AZITHROMYCIN; BENZACLIN; BENZOYL PEROXIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLAVARIS; CLENIA; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DOXYCYCLINE; DOXYCYCLINE HYCLATE; ERYTHROMYCIN; FINACEA; HYDROCORTISONE; ISOTRETINOIN; METROLOTION; METRONIDAZOLE; MINOCYCLINE; OCTREOTIDE; OVACE; PERMETHRIN; PIMECROLIMUS; PLEXION SCT; PREDNISONE; RETINOIC ACID; RETINOID; RETINOL; ROSAC; ROSANIL; ROSULA; SOTRET; SULFACETAMIDE; SULFONAMIDE; SULFUR; TAZAROTENE; TETRACYCLINE; TSUKUBAENOLIDE; UNINDEXED DRUG;

ATOPIC DERMATITIS; BURNING SENSATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONFERENCE PAPER; DERMATITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY REACTION; INFLAMMATION; LUPUS LIKE SYNDROME; MIGRAINE; NONHUMAN; PHOTOSENSITIVITY; PIGMENT DISORDER; ROSACEA; SIDE EFFECT; SKIN IRRITATION; SKIN MANIFESTATION; TOXIC EPIDERMAL NECROLYSIS; VERTIGO; VULVOVAGINITIS;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; ROSACEA;

EID: 17144366584     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Dahl MV. Pathogenesis of rosacea. Adv Dermatol. 2001;17:29-45.
2. Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed. 2003;2:43-47.
3. Shalita A, Leyden J. Mechanism-based selection of pharmacologic agents for rosacea. Cutis. 2004;73(suppl 1):15-18.
4. Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275.
5. Sauder DN, Miller R, Gratton D, et al. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatol Treat. 1997;8:79-85.
6. McClellan KJ, Noble S. Topical metronidazole. a review of its use in rosacea. Am J Clin Dermatol. 2000;1:191-199.
7. Wolf JE Jr. The role of topical metronidazole in the treatment of rosacea. Cutis. 2004;73(suppl 1):19-28.
8. Odom RB. The subtypes of rosacea: implications for treatment. Cutis. 2004;73(suppl 1):9-14.
9. Beutner KR, Lemke S, Czernielewski J. Patient acceptability of a new fragrance-free sulfacetamide/sulfur cleanser. Poster presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. P205.
10. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683.
11. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-1450.
12. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845.
13. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37.
14. Basta-Juzbasic A, Dobric I. The effect of local administration of corticosteroids on the course and therapy of rosacea [in Croatian]. Lijec Vjesn. 1989;111:89-93.
15. Brinkmeier T, Frosch PJ. Oral antibiotics with antiinflammatory/ immunomodulatory effects in the treatment of various dermatoses [in German]. Hautarzt. 2002;53:456-465.
16. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003;2:234-245.
17. Dahl MV. Rosacea subtypes: a treatment algorithm. Cutis. 2004;74(suppl 3):21-27.
18. Labeling requirements for systemic antibacterial drug products intended for human use. final rule. Fed Regist. 2003;68:6062-6081.
19. Berg M, Liden S. Postmenopausal female rosacea patients are more disposed to react with migraine. Dermatology. 1996;193:73-75.
20. Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol. 1983;119:211-214.
21. Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol. 1989;20:202-205.
22. Grosshans E, Michel C, Arcade B, et al. Rilmenidine in rosacea: a double-blind study versus placebo. Ann Dermatol Venereol. 1997;124:687-691.
23. Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol. 2004;50:107-108.
24. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001;44:995-998.
25. Antille C, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004;140:457-460.
26. Lubbe J, Stucky L, Saurat JH. Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream. Dermatology. 2003;207:204-205.
27. Breneman D, Savin R, VandePol C, et al. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43:381-387.
28. Swenor ME. Is permethrin 5% cream effective for rosacea? J Fam Pract. 2003;52:183-184.
29. Kocak M, Yagli S, Vahapoglu G, et al. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. a randomized double-blind placebo-controlled study. Dermatology. 2002;205:265-270.
30. Gupta AK. The strength of the evidence for various therapies in the management of rosacea. Poster presented at: 61st Annual Meeting of the American Academy of Dermatology; March 21-26, 2003; San Francisco, Calif. P54.
31. Bakar O, Demircay Z, Gurbuz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol. 2004;43:151-154.
32. McHugh R, Rice A, Sangha N, et al. A topical azithromycin preparation for the treatment of acne vulgaris and rosacea. J Dermatolog Treat. 2004;15:295-302.
33. Piérard-Franchimont C, Quatresooz P, Piérard GE. Incidental control of rosacea by somatostatin. Dermatology. 2003;206:249-251.
34. Heymann WR. Rosacea subtype-directed therapy. J Am Acad Dermatol. 2004;51:90-91.
35. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-587.
36. Quarterman MJ, Johnson DW, Abele DC, et al. Ocular rosacea. signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol. 1997;133:49-54.
37. Ta CN, Shine WE, McCulley JP, et al. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea. 2003;22:545-548.
38. Helm KF, Menz J, Gibson LE, et al. A clinical and histopathologic study of granulomatous rosacea. J Am Acad Dermatol. 1991;25:1038-1043.
39. Jansen T, Plewig G. Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities. Facial Plast Surg. 1998;14:241-253.
40. Rebora A. The management of rosacea. Am J Clin Dermatol. 2002;3:489-496.